Pharma major Dr Reddy’s Laboratories has launched Lamotrigine Orally Disintegrating Tablets in the US market following an approval by the US Food & Drug Administration (USFDA).
The tablets are a therapeutic equivalent generic version of Lamictal ODT (lamotrigine) Orally Disintegrating Tablets of GSK group of companies. They are indicated in the treatment of certain types of seizures.
The Lamictal ODT brand and generic had US sales of approximately $65.5 million for the most recent 12 months ending in July 2016, according to IMS Health.
Dr Reddy’s scrip gained 0.80 per cent on the Bombay Stock Exchange on Monday to end at Rs 3,078.65.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.